Full Text View
Tabular View
No Study Results Posted
Related Studies
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
This study is ongoing, but not recruiting participants.
Study NCT00055939   Information provided by National Cancer Institute (NCI)
First Received: March 6, 2003   Last Updated: July 23, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sarcoma
Additional conditions recognized in this trial
Rhabdomyosarcoma
More general conditions related to this trial
Myosarcoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Interventions listed in this trial
exatecan mesylate
Additional drug interventions recognized in this trial
Camptothecin
DX 8951
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Daiichi Sankyo Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services